BIOLOGICS US 2025

October 2 - 3, 2025 | San Diego, CA

Conference Brochure

Unlocking Future Insights in Proteins, Antibodies & ADCs Discovery & Development

4 Content Tracks

200 pre-arranged 1-2-1 meetings

13+ Partners

1,000+ Attendees

Composed of 3 Groundbreaking Programs!

- **Proteins & Antibodies**
- **ADC Discovery & Development**
- **Start Up Zone Program**

@NextGenBiomedOG NextGen Biomed by Oxford Global

Meet Your KEYNOTE SPEAKERS

DAY ONE | 09:15

STEVE TURNER

Chief Executive Officer **Pangio Biosystems** & Former Founding Chief Executive Officer, **PacBio**

DAY TWO | 09:00

RAY DESHAIES

Former Senior Vice President of Global Research, **Amgen**

Book Now! Complimentary Industry, Academic or Investor Guest Passes Available

Register Sponsor

Co-located with Discovery & Development US 2025

> More Information

WELCOME TO

Biologics US 2025

Oxford Global are pleased to share with you the 2025 program for the upcoming Biologics US conference in San Diego October 2 – 3.

Join us for 2 days full of exciting and cutting-edge science, celebrating the latest achievements and addressing the challenges in the field of biologics discovery & development. Featuring the Proteins & Antibodies and ADC Discovery & Development programs, our agenda showcases the latest advancement in AI & ML technologies, breakthroughs in translating ADC's in the clinic & solutions to complex development & manufacturing processes.

Attendees will benefit from the opportunity to interact and network with key industry leaders and potential collaborators during our thought-provoking interactive sessions and dedicated networking opportunities. Stay tuned for engaging discussions on 'Patient Advocacy Considerations For Clinical Success Of ADC Trials' and breakfast roundtable sessions on 'IP Considerations In Early Discovery & Development' & 'Antibody Discovery & Engineering in 2025 & Beyond' among others.

This year, Biologics US goes even further — co-located with Discovery & Development US 2025, offering 1000+ attendees the unique opportunity to engage across both communities and forging the path to the next generation of therapies that will transform lives and reshape the future of healthcare.

Eszter Sutowski Nagy
Senior Production Director,
Oxford Global

Unlock The Latest News & Insights

Sign up for our monthly newsletter to keep up with all things NextGen Biomed

Click Here

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Special Event Features

Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

LinkedIn
@OGConferences

WHAT'S NEW

Benefits Of Attending

Gain valuable insights from key innovators in biologics.
Take a deep dive into the latest AI/ML-guided antibody discovery workflows to accelerate building the next generation of blockbuster therapies.

Uncover the next generation of biologics research.
Gain the insights you need to overcome the challenges of identifying and validating novel targets, including multi-specifics, cell engagers & ADCs.

With new tools & platforms always under development,
our exhibition hall highlights the most promising products to help you meet your research goals and progress your targets towards the clinic.

Connect with your next collaborator during our engaging presentations in our Start-up Zone Program.
Hear inspiring presentations unveiling the latest breakthroughs from emerging biotech's, the latest collaborations with pharma & academia & spotlights on the most innovative start-ups!

Co-located with Discovery US & Formulation & Delivery US,
to attract 1000+ senior attendees across small and large molecule discovery & development.

With exciting new additions, including spotlight roundtable discussions and thought leadership-driven sessions,
this is the must-attend event to stay ahead of the innovations shaping the future of the biologics landscape.

DON'T MISS THESE

Interactive Features

16:15 | Day 1
Panel Discussion:
Strategic Decisions In Early R&D For Antibody Research & Discovery

09:35 | Day 2
Roundtable Discussion:
Emerging Targets In ADC Development

09:35 | Day 2
Roundtable Discussion:
Patient Advocacy Considerations For Clinical Success Of ADC Trials

09:35 | Day 2
Roundtable Discussion:
Antibody Discovery & Engineering

14:30 | Day 2
Panel Discussion:
Clinical Challenges In The Application Of Cell Engagers

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Special Event Features

Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

WHY PARTNER WITH

OXFORD GLOBAL?

At Oxford Global, our mission is to curate personalised experiences that foster community and inspire innovation.

We believe in the power of networking, connection, and knowledge to deliver quality products and services that exceed expectations. Partnering with Oxford Global means having a dedicated team committed to helping you achieve your goals and navigating the industry's ever-changing landscape.

- **Arrange 1-1 Meetings**

Benefit from guaranteed one-to-one face time with your key prospects, with detailed pre-meeting information provided to enable effective and productive conversations.

- **Speaking Opportunities**

Showcase your company's recent work to a relevant and highly engaged audience.

- **Host Panel & Roundtable Discussions**

Feature alongside key opinion leaders to discuss current hot topics and highlight your company's expertise.

- **Organise Workshops**

Demonstrate best practice within the industry in front of your peers with case studies from your clients.

- **Exhibit your Products & Solutions**

Promote your offerings and ensure delegates know where to find you with a prominent brand presence in the exhibition hall.

- **Digital Marketing & Lead Generation**

Accessing the Oxford Global database, amplify your thought leadership and branding messaging through our digital content initiatives.

LEARN MORE

DRIVE INNOVATION & ACCELERATE RESEARCH

Who Is Partnering?

Gold Sponsors

Ajinomoto · BIO•PHARMA SERVICES · GenScript Scripting Possibilities · Lonza · NOF · QUANTUM SI

Silver Sponsors

Alloy Therapeutics · PipeBio A Benchling company · SCIEX The Power of Precision

Bronze Sponsors

GeneFrontier · PAIA · rapid novor · sapio sciences

Network & Program Sponsors

ATEM STRUCTURAL DISCOVERY · ARL BIO PHARMA · BIOINTRON · DNASCRIPT · HAMILTON · KEY2MEDS · NONA BIOSCIENCES · NOVILYTIC · nicoya · octapharma · SGS · teknova · ThermoFisher SCIENTIFIC

BROCHURE CONTENTS

Welcome
Benefits of Attending
Sponsors
Agenda at a Glance
Special Event Features
Speakers
Full Programme: Day One
Full Programme: Day Two
Venue Information

Book Now

LinkedIn @OGConferences

SPECIAL EVENT FEATURES

Big Attendance Meets Intimate Connections

An unmissable journey awaits you: from immersive panels and workshops, to a garden party to celebrate. Experience an event that celebrates meaningful, one-on-one connections in a dynamic, bustling atmosphere. With Biologics US 2025, enjoy a vibrant crowd with the warmth of personal interactions and curated experiences.

‘Innovation & Breakthroughs Under the Stars’ Garden Party

Join us for our ‘Innovations & Breakthroughs Under the Stars’ Garden Party at the end of Day 1 at the Eventide Gardens, Sheraton San Diego by the Marina. This is your chance to mix and mingle with the brightest minds in the industry in a vibrant, open-air setting, complete with gourmet food stations, refreshing drinks, and a relaxed garden-party vibe.

Whether you’re coming to connect, unwind, or simply enjoy a summer evening, this is the can’t - miss celebration of the season, all under the California night sky.

Day 1 Opening Keynote Address: The Single-Molecule Revolution Makes Landfall In Drug Discovery: Where We Are Now & What’s To Come

- STEVE TURNER, Chief Executive Officer, Pangio Biosystems & Former Founding Chief Executive Officer, PacBio
- Don’t miss Steve opening the event with his talk at 9:15 on Day 1

Day 2 Opening Keynote Address: How ‘Proximity Medicines’ Are Transforming Pharmacotherapy

- RAY DESHAIES, Former Senior Vice President of Global Research, Amgen
- Ray’s talk will be taking place at 9:00 on Day 2

Interactive Panel Discussions

Get up close and personal with industry trailblazers in our variety of roundtables and panel discussions. Hear firsthand how leaders are tackling big challenges in implementing novel technologies such as AI/ML, driving innovation, and shaping the future of drug development. Expect meaningful debates, bold ideas, and valuable insights you won’t find in a typical presentation

The Start Up Zone Program

The Start Up Zone is designed to support young start-ups working on new technologies, platforms, solutions to showcase their innovative thinking and bring new ideas.

To apply, visit the website or email Faye Moffat at f.moffatt@oxfordglobal.com

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Special Event Features

Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

Proteins & Antibodies
Program Overviews

Join leading scientific experts through our annual Proteins & Antibodies program to address critical strategies, scientific breakthroughs and the latest technological advancements in protein & antibody engineering, AI/ML-guided antibody discovery and the latest case studies in the development of next-generation biotherapeutics.

Day 1 Track 1: Protein & Antibody Discovery & Engineering

- Novel engineering strategies to enhance antibody functions
- Advanced technologies for new antibody discovery
- Computational advances in protein engineering
- AI-driven antibody design & optimization
- Applications of bioanalytical tools
- Use cases & prediction tools

Day 2 Track 1: Tools & Technologies For Antibody Discovery & Engineering

- AI/ML approaches to antibody engineering
- AI/ML & deep learning tools in antibody engineering
- AI-driven structural prediction
- Addressing difficult targets with display technologies
- Developing novel in vitro display technologies for antibody discovery & engineering
- Innovative de novo antibody generation
- Structural approaches to protein engineering
- Computational and analytical tools for protein engineering

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Antibody Engineering
- Protein Engineering
- Antibody Discovery
- Biologics Discovery
- Biologics Development
- Protein Design
- AI/ ML for Protein Design
- NextGen Biologic Targets

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Antibody Generation
- Bispecific Antibody Design
- Expression Platforms
- Display Technologies
- Computational Tools
- Discovery Platforms
- Antibody Optimization
- Antibody Humanization

BROCHURE CONTENTS

Welcome
Benefits of Attending
Sponsors
Agenda at a Glance
Special Event Features
Speakers
Full Programme: Day One
Full Programme: Day Two
Venue Information
Book Now



ADC Discovery & Development
Program Overviews

Join industry leaders at our ADC Discovery & Development program to discuss cutting edge technological advancements in ADC discovery, the latest case studies in translating ADC into the clinic, and manufacturing considerations.

Day 1 Track 2: Engineering Conjugates For ADC Design & Novel Targets

- Strategies to optimise the design of ADCs
- Linker/payload technologies to achieve better therapeutic index
- Tailoring ADC design to specific targets
- Validating novel ADC targets, including next generation conjugates
- Translational biomarkers to support research from discovery to the clinic
- Antibody fragments for ADC optimisation

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- ADC Discovery
- Computational Biology
- Engineering Conjugates
- ADC Design
- CMC & Manufacturing
- ADC Validation
- ADC Engineering
- ADC Chemistry

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Bioconjugation
- Antibody Generation
- Linker Chemistry
- Payload Selection
- Antibody Generation
- Linker Optimization
- Payload & Linker Synthesis
- Process Development

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Special Event Features

Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

ALL PROGRAMS

Confirmed Speakers

SPOTLIGHT SPEAKERS

DAY ONE | 17:30

HARPINDER SAINI,
Senior Scientist, Biochemical and Cellular Pharmacology-gRED, Genentech

DAY ONE | 10:00

RYAN STAFFORD,
Executive Director, Protein Engineering, 3T Biosciences

DAY ONE | 14:25

SIVA DEVANABOYINA, Senior Principal Scientist, Amgen

DAY ONE | 19:10

UDAYA RANGASWAMY,
Director of Translational Biology,
Rondo Therapeutics

DAY TWO | 10:00

NATHAN ALVES,
Research Director & Associate Professor, Indiana University

WYATT MCDONNELL
Co-Founder & Chief Executive Officer, Infinimmune

RYAN STAFFORD
Executive Director, Protein Engineering, 3T Biosciences

HETAL SARVAIYA
Director, DMPK-BA, AbbVie

SIVA DEVANABOYINA
Senior Principal Scientist, Amgen

JULIO A. CAMARERO
Professor in Pharmaceutical Sciences, University of Southern California

UDAYA RANGASWAMY
Director of Translational Biology, Rondo Therapeutics

WENYU LIU
Senior Principal Scientist, Genentech

HARPINDER SAINI
Senior Scientist, Biochemical and Cellular Pharmacology-gRED, Genentech

ALLISON COLTHART
Prinicpal Scientist, Seismic Therapeutics

ERIC JANEZIC
Principal Scientist, Genentech

PRIYA GANESAN
Senior Scientist, Amgen

RAY DESHAIES
Former Senior Vice President of Global Research, Amgen

NATHAN ALVES
Research Director & Associate Professor, Indiana University

TWINKLE CHRISTIAN
Senior Principal Scientist & Early Candidate Lead, Amgen

A. JAMES LINK
Professor of Chemical & Biological Engineering, Princeton University

VIRAL DAVRA
Senior Scientist, Xencor

JAN SCHNITZER
Founder & Chief Executive Officer, PRISM

ALYCIA SHILTON-LLOYD
Executive Director, Hematology-Oncology, Patient Innovation & Engagement, Merck & Co., Inc.

DENISE STECKEL
Head of Clinical Collaborations Development, Genentech

DEEPAK KANOJIA
Principal Scientist, Mythic Therapeutics

BISHNU NAYAK
Senior Director, Neologics Bio

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Special Event Features

Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

Day One | October 2 2025

Welcome & Keynote Address
Conference Room 4 Coral 4

08:50 **Oxford Global's Welcome Address By Eszter Sutowski Nagy, Senior Production Director, Oxford Global**

09:00 

KEYNOTE ADDRESS: **THE SINGLE-MOLECULE REVOLUTION MAKES LANDFALL IN DRUG DISCOVERY: WHERE WE ARE NOW AND WHAT'S TO COME**

STEVE TURNER, Chief Executive Officer **Pangio Biosystems** and Former Founding Chief Executive Officer, **PacBio**

Q&A session & transition time between conference rooms

Track Chair:
WENYU LIU, Senior Principal Scientist, Genentech

09:35 **Insights Into Successful Industry Clinical Collaborations**

- Why do we establish clinical collaborations with external companies?
- Industry Clinical Collaborations (ICC) at Roche
- Drugs combinations in ICC
- Successes & challenges with commercial drugs & novel combinations

DENISE STECKEL, Head of Clinical Collaborations Development, **Genentech**

10:00 - 11:00 **MORNING BREAK & REFRESHMENTS**

1-2-1 Meetings x3 | Poster Displays

PROTEINS & ANTIBODIES PROGRAM

PROTEIN & ANTIBODY DISCOVERY & ENGINEERING
CONFERENCE ROOM 4 CORAL 4

Morning Track Chair:
WENYU LIU, Senior Principal Scientist, Genentech

Solution Provider Presentation

11:00 GenScript

Senior Representative, **Genscript**

ADC DISCOVERY & DEVELOPMENT PROGRAM

ENGINEERING CONJUGATES FOR ADC DESIGN & NOVEL TARGETS
CONFERENCE ROOM 5 CORAL 5

Morning Track Chair:
HETAL SARVAIYA, Director, DMPK-BA, AbbVie

Platinum Solution Provider Presentation

For sponsorship opportunities please contact sponsorship@oxfordglobal.com

Q&A session & transition time between conference rooms

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Special Event Features

Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

Day One | October 2025

PROTEINS & ANTIBODIES PROGRAM

PROTEIN & ANTIBODY DISCOVERY & ENGINEERING

CONFERENCE ROOM 4 CORAL 4

GLIMPSE-1: Engineering Better Antibodies With A Human-First Language Model

- Learning from human repertoires: GLIMPSE-1 is trained exclusively on paired human antibody sequences, capturing the biological patterns and constraints that evolution has optimized over millions of years - leading to state-of-the-art performance in humanization benchmarks
- From sequences to therapeutics: We demonstrate GLIMPSE-1's practical utility by engineering antibodies with improved affinity, cross-species reactivity, and developability profiles across multiple therapeutic targets, while maintaining critical properties like stability and expression
- Exploring functional diversity: Using GLIMPSE-1, we created highly divergent variants of a marketed antibody with <90% sequence identity that retain full functionality - showcasing how human-trained models can navigate viable sequence space for intellectual property and therapeutic applications

WYATT MCDONNELL, Co-Founder & Chief Executive Officer,
Infinimmune

11:25

Tackling The Unique Challenges Of GPCRs With An Integrated High-Throughput Antibody Discovery Workflow

Tackling the unique challenges of GPCRs demands innovative solutions. We present an integrated high-throughput antibody discovery workflow that leverages native-like antigen presentation, rapid screening, and tailored selection strategies. A case study demonstrates its success in delivering high-quality, sequence diverse, antibodies against a difficult GPCR target.

11:50

Alloy Therapeutics

JOHN LIPPINCOTT, Vice President of Therapeutic Discovery Strategies.
Alloy Therapeutics

ADC DISCOVERY & DEVELOPMENT PROGRAM

ENGINEERING CONJUGATES FOR ADC DESIGN & NOVEL TARGETS

CONFERENCE ROOM 5 CORAL 5

Bioanalytical Strategy For Engineered Multispecifics & Drug Conjugates

This presentation will provide considerations and recommendations on the bioanalytical strategy for the characterization and in-vivo PK assessment of multispecifics and engineered antibodies. The emergence of biologic modalities like multispecifics and engineered antibodies presents exciting opportunities and unique challenges in drug development due to their diverse structures and complex mechanisms. This presentation explores strategies for comprehensive characterization of these molecules, focusing on stability, post-translational modifications, and choosing optimal bioanalytical platforms and assays for accurate in vivo measurements. Through case studies using LC-MS-based assays and advanced techniques, it aims to offer insights into overcoming bioanalytical challenges and effectively advancing these innovative therapies from discovery to development.

HETAL SARVAIYA, Director, DMPK-BA,
AbbVie

Q&A session & transition time between conference rooms

Maximizing The Performance Of Antibody Conjugates Through AJICAP Technology: Site-Specific Conjugation For Flexible DAR Control & Linker Selectively Cleaved In Tumor

AJICAP Technology provides a comprehensive solution for optimizing antibody-drug conjugates & oligonucleotide conjugates by addressing key challenges such as DAR control, expanding the therapeutic window, & improving stability. Our site-specific conjugation method uses Fc affinity peptides to generate homogeneous ADCs without redox chemistry or column purification. This enables scalable production of DAR1, DAR2, DAR4, DAR8, DAR10, and dual-payload formats. Over 60 grams of GMP-grade ADCs have been successfully manufactured. The AJICAP linker improves plasma stability and hydrophilicity compared to traditional valine-citrulline inkers, minimizing off-target payload release and enhancing tumor-selective payload cleavage. This expands the therapeutic window & improves the safety profile. In oligonucleotide conjugates, the DAR1 format enabled by AJICAP significantly enhances the biological stability & physicochemical properties, demonstrating its potential as a robust therapeutic modality. AJICAP is also applicable to next-generation conjugates, including proteins, lipid nanoparticles (LNPs), and PROTACs. We have conducted various in vivo studies to validate the versatility and utility of our platform across multiple modalities.

Ajinomoto BIO•PHARMA SERVICES

YUSAKU NOMURA, Business Development,
Ajinomoto

12:15 - 13:35

LUNCH BREAK

1-2-1 Meetings x4

Poster Displays

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Special Event Features

Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

Day One | October 2025

PROTEINS & ANTIBODIES PROGRAM

PROTEIN & ANTIBODY DISCOVERY & ENGINEERING

CONFERENCE ROOM 4 CORAL 4

ADC DISCOVERY & DEVELOPMENT PROGRAM

ENGINEERING CONJUGATES FOR ADC DESIGN & NOVEL TARGETS

CONFERENCE ROOM 5 CORAL 5

13:35

Benchling + PipeBio: A Next-Generation Antibody Solution

Traditionally antibody discovery has depended on many disjoint point solutions. By combining the power of PipeBio's best-in-class antibody sequence analysis with Benchling's comprehensive suite of R&D tools for biologics, we are revolutionizing how scientists approach antibody discovery.

MEGAN DUECK, Scientific Solutions Consultant,
PipeBio

Development & Evaluation Of Novel Cleavable Pendant Type PEG Linkers For ADCs

We developmed cleavable pendant-type PEG linkers enabling DAR8-ADCs with reduced hydrophobicity. PEG8/PEG12 linkers showed superior PK & efficacy over DAR4-ADCs. Notably, DAR8-ADC with PEG12 showed high tolerability with no weight loss in vivo.

TAIKI MORITA, Life Science Division, Senior Scientist,
NOF Corporation

Q&A session & transition time between conference rooms

14:00

Targeting ASGR1 With Catabolic Antibodies For Therapeutic Applications

- Detailed PK/ADME characterization of catabolic anti-ASGR1 antibodies
- Targeting ASGR1 for depleting soluble antigens

SIVA DEVANABOYINA, Senior Principal Scientist,
Amgen

Achieving Ultra-Low Dose Therapy Via Precision Transvascular Pumping Of Biologics & Nanoparticles

- Precision targeting ideally means 100% iv therapeutic dose penetrating a single tissue in minutes
- Current biologics require high therapeutic doses because poor passive extravasation into desired solid tissues (<1%) limits potency, efficacy and safety
- Targeting the endothelial caveolae pumping system enables precision targeting (>80%) and ultra low dose therapeutic efficacy

JAN SCHNITZER, Founder & Chief Executive Officer,
PRISM

Q&A session & transition time between conference rooms

14:25

Unleashing The Power Of Cell-Free: PURExpress® For Protein Engineering & Discovery

PURExpress is our unique rebuilt cell-free protein expression system. It's easy to customize for various applications, and useful for high throughput screening of various kinds of biologics, difficult-to-express protein or novel modalities having the synergy with the AI/ML platform.

TAKASHI EBIHARA, Chief Operating Officer,
Gene Frontier

Enhanced Biotherapeutic Characterization Using The ZenoTOF 8600 System

This presentation highlights the benefits offered by the ZenoTOF 8600 system for comprehensive biotherapeutic characterization, including:

- Enhanced intact and native MS analysis for accurate mass measurement and impurity assessment with reduced sample consumption
- Rapid sequence analysis using subunit and middle-down MS workflows
- Sensitive detection and confident identification of low-abundant proteoforms, enhanced sequence variant analysis, accurate localization of PTMs, and clear isomer differentiation using an electron-activated dissociation (EAD)-based peptide mapping workflow

HAICHUAN LIU, Manager, Protein Characterization,
Sciex

14:50 - 15:50

AFTERNOON BREAK

1-2-1 Meetings x3

Poster Displays

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Special Event Features

Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

Day One | October 2025

PROTEINS & ANTIBODIES PROGRAM

PROTEIN & ANTIBODY DISCOVERY & ENGINEERING

CONFERENCE ROOM 4 CORAL 4

Afternoon Track Chair:
WENYU LIU, Senior Principal Scientist, Genentech

First In Human - Antibody Discovery Using Mass Spectrometry & Human Blood

We use REpAb® mass spectrometry-based sequencing to profile circulating antibodies directly from human blood. This protein-first approach captures functional, naturally selected antibodies, enabling discovery from diverse antibody repertoires.

15:50

OLGA KAPUSTINA, Senior Scientific Sales Executive,
Rapid Novor

Q&A session & transition time between conference rooms

PANEL DISCUSSION: **Strategic Decisions In Early R&D For Antibody Research & Discovery** — INTERACTIVE

- Antibody engineering
- Antibody design
- Latest technological development
- Importance of CDMO partnerships

16:15

Moderator: PAUL JORJORIAN, Vice President Development and Scientific Solutions, **Thermo Fisher**

Panellists:

16:40

WYATT MCDONNELL, Co-Founder & Chief Executive Officer, **Infinimmune**

ALLISON COLTHART, Principal Scientist, **Seismic Therapeutics**

TUHIN DAS, Adjunct Professor, **Temple University**

Q&A session & transition time between conference rooms

Novel Method To Determine Biologics Affinity And Kinetics On Living Cells

Characterizing the binding parameters (ka, kd, KD) of antibody:receptor interactions is crucial in drug discovery. However, complex antibodies and/or receptors are not always amenable to traditional protein-based methods, necessitating cell-based binding assays. We developed a pre-equilibrium assay to simultaneously determine the binding kinetics of up to 30 therapeutic Abs on living cells.

17:05

ERIC JANEZIC, Principal Scientist,
Genentech

Q&A session & transition time between conference rooms

ADC DISCOVERY & DEVELOPMENT PROGRAM

ENGINEERING CONJUGATES FOR ADC DESIGN & NOVEL TARGETS

CONFERENCE ROOM 5 CORAL 5

Afternoon Track Chair:
JACK ROGERS, Director of Neurochemistry, Harvard University

High Throughput Developability Assays As A Tool For PK Prediction: How Far Have We Come?

In this talk we will introduce the PAIA portfolio of high throughput developability assays and show data from a recent industry collaboration aiming at the prediction of PK for a published set of Mabs with a number of different assay and analytical methods. Furthermore, we will be focusing on assay data quality, demonstrating reproducibility and precision of the PAIA developability assays. Lastly, we will be providing a quick preview of assays currently in development at PAIA

SEBSTIAN GIEHRING, Chief Executive Officer,
PAIA Biotech

Q&A session & transition time between conference rooms

Anatomy Of A High Concentration Biologic

High concentration biologics are complex to manufacture and deliver with patient centric initiatives. This presentation will focus on the design space with an optimized TPP (target product profile), early engagement of pivotal multidisciplinary stakeholders, interdependency of critical attributes during product development and key patient centric milestones across product development lifecycle of a high concentration biologic.

TWINKLE CHRISTIAN, Senior Principal Scientist & Early Candidate Lead,
Amgen

Q&A session & transition time between conference rooms

Patient Populations For Clinical Trial Success

ALYCIA SHILTON-LLOYD, Executive Director, Hematology-Oncology, Patient Innovation & Engagement,
Merck & Co., Inc.

Q&A session & transition time between conference rooms

Pre-Clinical Considerations For Development Of ADCs

- ADC development pathway overview
- Target selection & antibody production
- Payload / linker / conjugation / formulation impact

NATHAN ALVES, Research Director & Associate Professor,
Indiana University

Q&A session & transition time between conference rooms

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Special Event Features

Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

Day One | October 2025

PROTEINS & ANTIBODIES PROGRAM

PROTEIN & ANTIBODY DISCOVERY & ENGINEERING

CONFERENCE ROOM 4 CORAL 4

17:30

Antibody Discovery For Lung Cancer

DEEPAK KANOJIA, Principal Scientist,
Mythic Theraputics

17:55

Precision & Sensitivity In The Gut: Addressing Matrix Interference Challenges In IBD Bioanalysis

- Fecal sample bioanalysis can be crucial in IBD to understand biodistribution of therapeutic molecules as well as study various disease biomarkers
- The inherent complexity of fecal matrices and pronounced matrix interferences present substantial challenges for the development of sensitive bioanalytical methods
- Our study systematically evaluated different bioanalytical platforms and mitigation strategies to reduce matrix interference in fecal samples, thereby enhancing assay sensitivity

HARPINDER SAINI, Senior Scientist, Biochemical and Cellular Pharmacology-gRED,
Genentech

ADC DISCOVERY & DEVELOPMENT PROGRAM

ENGINEERING CONJUGATES FOR ADC DESIGN & NOVEL TARGETS

CONFERENCE ROOM 5 CORAL 5

17:30

Therapeutic Targeting Of Intracellular PPIs In Cancer With Bioactive Cyclotides

We've developed a high-throughput cell-based screening method for genetically encoded libraries of cyclotides, aiming to select novel cyclotides that can inhibit specific intracellular protein-protein interactions. In particular, we will present data on novel cyclotides able to inhibit the Hdm2/HdmX E3 ligase activity (cyclotide MCo-52-2-cTAT) and the kinase activity of c-RAF (cyclotide MCo-RR7-cTAT). Both cyclotides were active in different cancer cell lines and displayed in vivo efficacy in various murine models of colorectal, pancreatic, and lung carcinomas.

JULIO A. CAMARERO, Professor in Pharmaceutical Sciences,
University of Southern California

17:55

Overcoming Challenges In Immunogenicity Testing For T-Cell Bispecifics

- Introduction to T Cell bispecific biotherapeutics and its immunogenicity strategy
- Case study#1: Characterization of the anti-drug antibody domain specificity of a bispecific biotherapeutic and its potential clinical impacts
- Case study#2: Redevelopment of a clinical ADA assay to enable the immunogenicity assessment of a bispecific antibody biotherapeutic

WENYU LIU, Senior Principal Scientist,
Genentech

Q&A session & transition time between conference rooms

CLOSE OF DAY ONE

18:20

Innovations & Breakthroughs Under the Stars Garden Party at Eventide Gardens, Sheraton San Diego

Join us for our 'Innovations & Breakthroughs Under the Stars' Garden Party at the end of Day 1 at the Eventide Gardens, Sheraton San Diego by the Marina. This is your chance to mix and mingle with the brightest minds in the industry in a vibrant, open-air setting, complete with gourmet food stations, refreshing drinks, and a relaxed garden-party vibe. Whether you're coming to connect, unwind, or simply enjoy a summer evening, this is the can't - miss celebration of the season, all under the California night sky.

Welcome Address by Dr Rick Ewing, Vice President, Head of Chemistry, Rapafusyn Pharmaceuticals

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Special Event Features

Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

Day Two | October 3 2025

Keynote Address
Conference Room 4 Coral 4

Track Chair: TUHIN DAS, Adjunct Professor, Temple University

09:00

KEYNOTE ADDRESS: **How 'Proximity Medicines' Are Transforming Pharmacotherapy**

Multispecific medicines - both large and small molecule - are on the ascendancy. Half of the 72 FDA-approved multispecific drugs have gained approval since 2020, and from 2022-24, multispecifics accounted for 1/6th of FDA approvals. Among the different categories of multispecific drugs, proximity medicines are of particular interest. These medicines typically work by either localizing the therapeutic molecule or recruiting a regulatory mechanism in the body to modulate the target. I will discuss the advantages conferred by multispecificity with particular emphasis on proximity medicines, and will describe a category of proximity medicines – LOCKTACs – that work by stabilizing a pre-existing complex.

RAY DESHAIES, Former Senior Vice President of Global Research,
Amgen

Q&A session & transition time between conference rooms

PROTEINS & ANTIBODIES PROGRAM

TOOLS & TECHNOLOGIES FOR ANTIBODY DISCOVERY & ENGINEERING

CONFERENCE ROOM 4 CORAL 4

ROUNDTABLE DISCUSSIONS IN CORAL FOYER

09:35

DISCUSSION 1:
Emerging Targets In ADC Development

- Next generation of ADCs
- Identifying ADC targets
- Novel approaches for bispecific target selection & validation

Co-Moderators: JAN SCHNITZER, Founder & Chief Executive Officer, **PRISM** & NATHAN ALVES, Research Director & Associate Professor, **Indiana University**

DISCUSSION 2:
Antibody Discovery & Engineering

- Accelerating discovery processes to optimize the development of antibodies
- Novel therapeutic applications
- Emerging trends and future directions

Moderator: BISHNU NAYAK, Senior Director, **NeoLogics Bioscience**

DISCUSSION 3:
Patient Advocacy Considerations For Clinical Success Of ADC Trials

- Patient selection
- Challenges in toxicity
- Regulatory considerations

Moderator: ALYCIA SHILTON-LLOYD, Executive Director, Hematology-Oncology, Patient Innovation & Engagement, **Merck & Co., Inc.**

Q&A session & transition time between conference rooms

10:00

Engineering Antibodies Against pHLA Targets Using A High-Throughput Screening Platform

We have developed 3T-TRACE, a high-throughput yeast-display platform to discover novel targets from patient immune responses, and 3T-PRIME to engineer TCR mimic (TCRm) antibodies for bispecific T cell engager therapies. We synergistically use these platforms to develop highly specific TCRms for solid tumors and de-risk off-target toxicity concerns.

RYAN STAFFORD, Executive Director, Protein Engineering,
3T Biosciences

Q&A session & transition time between conference rooms

10:25

Solution Provider Presentation

Lonza

Senior Representative,
Lonza

10:50 - 11:50

MORNING BREAK & REFRESHMENTS

1-2-1 Meetings x3

Poster Displays

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Special Event Features

Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

Day Two | October 3 2025

PROTEINS & ANTIBODIES PROGRAM

TOOLS & TECHNOLOGIES FOR ANTIBODY DISCOVERY & ENGINEERING

CONFERENCE ROOM 4 CORAL 4

Digital Transformation In Antibody Discovery

A unified lab informatics approach to multi-omics data management: in silico screening to candidate selection.

11:50

VERONICA DEFELICE, Director of Biologic Products,
Sapio Sciences

Q&A session & transition time between conference rooms

CD28-Based Costimulatory Bispecific Antibodies For The Treatment Of Solid Tumors

12:15

•Bispecific antibodies targeting costimulatory receptors could enable robust T cell responses where signal 1 alone is insufficient to drive anti-tumor immunity
•Rondo therapeutics has developed RNDO-564, a CD28 and Nectin-4 targeted bispecific antibody for the treatment of metastatic bladder cancer. Preclinical characterization of RNDO-564 will be presented

UDAYA RANGASWAMY, Director of Translational Biology,
Rondo Therapeutics

Q&A session & transition time between conference rooms

Next-Generation Protein Sequencing For Antibody Characterization

Next-Gen Protein Sequencing on Quantum-Si's Platinum® benchtop instrument, allows scientists to sequence through proline-rich regions commonly found in mAbs. These results deliver high-resolution insights into antibody sequence and modification.

12:40

KENDRICK NGUYEN, Staff Scientist, Application Development,
Quantum Si

13:05 - 14:05 **LUNCH BREAK**

1-2-1 Meetings x3

Poster Displays

Afternoon Track Chair:
UDAYA RANGASWAMY, Director of Translational Biology, Rondo Therapeutics

Multi Specific Immune Cell Engagers In Immunology

14:05

• Next generation multi-specifics

PRIYA GANESAN, Senior Scientist,
Amgen

Q&A session & transition time between conference rooms

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Special Event Features

Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

Day Two | October 3 2025

PROTEINS & ANTIBODIES PROGRAM

TOOLS & TECHNOLOGIES FOR ANTIBODY DISCOVERY & ENGINEERING

CONFERENCE ROOM 4 CORAL 4

14:30

PANEL DISCUSSION: **Clinical Challenges In The Application Of Cell Engagers**

INTERACTIVE

- Next generation cell engager applications
- Challenges in clinical translation
- Cell engagers in oncology

Panellists:

PRIYA GANESAN, Senior Scientist, **Amgen**

WENYU LIU, Senior Principal Scientist, **Genentech**

UDAYA RANGASWAMY, Director of Translational Biology, **Rondo Therapeutics**

Q&A session & transition time between conference rooms

14:55

Using Machine Learning To Design FcgRIIb Selective Fc Domains For The Treatment Of Autoimmune Diseases

FcgRIIb, the sole inhibitory Fc receptor, regulates immune and inflammatory responses. FcgRIIb-anchored agonists may enhance agonism by preventing inflammatory cytokine responses and reducing APC activation. Using machine learning integrated with structure-based design, we engineered Fc regions that selectively bind FcgRIIb over other activating receptors. Two applications of these selective Fc regions will be presented.

ALLISON COLTHART, Principal Scientist,
Seismic Therapeutics

Q&A session & transition time between conference rooms

15:20

XmAb657 & Plamotamab: Advancing CD19 & CD20 Bispecific T-Cell Engagers For Autoimmune Disease Therapy

- XmAb657 and Plamotamab are bispecific T-cell engagers targeting CD19 and CD20, designed to redirect cytotoxic T cells for selective and sustained B-cell depletion in autoimmune disease
- Leveraging Xencor's XmAb® bispecific Fc domain platform, these molecules are engineered to optimize stability, potency, & controllable T-cell activation while maintaining favorable safety profiles
- Emerging preclinical and clinical data support their potential to deliver durable immune modulation, offering a differentiated therapeutic approach compared to conventional B-cell–directed therapies

VIRAL DAVRA, Senior Scientist,
Xencor

Q&A session & transition time between conference rooms

15:45

Repurposing Graspetide Synthetase To Make Cyclic Peptides

- Graspetides are a large class of peptide natural products that include peptide macrocycles
- We have demonstrated that a specific graspetide biosynthetic enzyme is highly promiscuous and can cyclize a wide array of peptide and protein substrates
- This approach to cyclic peptide biosynthesis works both in E. coli and in vitro, opening up new possibilities for the construction of cyclic peptide libraries

A. JAMES LINK, Professor of Chemical & Biological Engineering,
Princeton University

16:10

END OF CONFERENCE

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Special Event Features

Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

VENUE INFORMATION

Soak in Stunning Waterfront Views at Sheraton's San Diego Bay Hotel

Sheraton San Diego Resort dazzles guests with spectacular views of the marina or downtown skyline. Experience San Diego with a central location in the heart of the harbor, yet just minutes from San Diego Airport with a free shuttle.

Enjoy being near downtown, Gaslamp Quarter, San Diego Zoo, and Petco Park, for a fun time in the city. Our newly renovated marina tower shines with coastal hues and modern amenities and our light-filled accommodations have a private balcony with seating. Enjoy picturesque views of the bay or marina in the classic bay tower guest rooms that also boast private balconies with seating. Stop by BreweryX for a refreshing brew or discover authentic Baja dishes at Rumorosa. Enjoy our sprawling outdoor pool complex, with ample opportunities to soak in the San Diego sun or lounge in poolside cabanas, cocktail in hand. Featuring over 130,000 sq ft of venue space accentuated by waterfront views, our San Diego Harbor Hotel is an inspired choice for weddings and meetings.

DIRECTIONS BY AIR

From San Diego International Airport (SAN), the hotel is just 1.5 miles from the airport.

Shuttle: Use the free Sheraton shuttle, available at Terminal 1 & Terminal 2. Look for the "Hotel Courtesy Shuttle" sign. If Shuttle is unavailable: Take the 992 bus from the airport to the Harbor Island Drive & Sheraton Way stop (5-minute ride). Walk 5 minutes to the hotel.

DIRECTIONS BY TRAM/BUS

The total journey from downtown via tram and bus should take around 20-30 minutes.

- Take the San Diego Trolley:
  - Use the Green Line or another line that connects to the Santa Fe Depot station.
- Transfer to Bus or Walk:
  - From Santa Fe Depot, take Bus 992 (Airport Route) toward the San Diego International Airport. Exit at the hotel stop near Harbor Island.
- Alternatively, walk approximately 30 minutes (1.5 miles) along Harbor Drive to the hotel.

SHERATON
EST. 1937

Sheraton San Diego Hotel

1380 Harbor Island Drive,
San Diego, CA

Explore the Hotel

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Special Event Features

Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now